Retatrutide vs Tirzepatide

Both are classed here as GLP-1 / incretin agonists, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is appetite control, fat loss, and metabolic health. On this site's goal weighting — an editorial priority score, not a measure of effect size — Retatrutide rates 5/5 for appetite control and Tirzepatide rates 5/5.

This is the part that decides most of it. Tirzepatide has an approved label and the randomized trial package behind it — head-to-head trials put its average weight loss above semaglutide. Retatrutide has controlled human trials behind it, without an approval — phase 3 is still running, so there is no long-term safety record. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

Half-lives are close — 6 days for Retatrutide, 5 days for Tirzepatide — and both are dosed once a week, so the rhythm of actually running them is the same.